Latest Lung Cancer News | NSCLC/SCLC Treatment Information

Lung Cancers News

LUNG CANCER ADVISOR

Lung Cancers News

Novel Bispecific Antibody Gets Breakthrough Therapy Status for NSCLC

The FDA has granted Breakthrough Therapy designation to JNJ-6372 (Janssen) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
Next post in Lung Cancer News